Raymond P. Ahlquist

From WikiProjectMed
(Redirected from Raymond Ahlquist)
Jump to navigation Jump to search
Raymond Perry Ahlquist
Courtesy of the National Library of Medicine.
Born(1914-07-26)26 July 1914
Missoula, Montana
Died15 April 1983(1983-04-15) (aged 68)
Augusta, Georgia
NationalityAmerican
CitizenshipAmerican
Alma materUniversity of Washington
Known forDiscovery of adrenoceptor subtypes
AwardsLasker award (1976)
Scientific career
FieldsPharmacology
InstitutionsMedical College of Georgia

Raymond Perry Ahlquist (July 26, 1914 – April 15, 1983) was an American pharmacist and pharmacologist. He published seminal work in 1948 that divided adrenoceptors into α- and β-adrenoceptor subtypes. This discovery explained the activity of several existing drugs and also laid the ground work for new drugs including the widely prescribed beta blockers.[1][2]

Early life and education

Ahlquist was born on July 26, 1914, in Missoula, Montana. Both of his parents came from Sweden. His father was an auditor at the Railway Company Northern Pacific Railway. In 1940, Ahlquist graduated with a Ph.D. degree in pharmacology from the University of Washington in Seattle, the first person to be awarded such a degree from that institution.

Career and research

Ahlquist spent four years as a faculty member at South Dakota State University in Brookings. In 1944 he became assistant professor of pharmacology at the Medical College of Georgia in Augusta. In 1946 he was appointed associate professor in the same institution and from 1948 to 1963 he was the chair of pharmacology. In 1963 he was appointed associate dean for basic sciences and research coordinator for the medical college. Between 1970 and 1977 he was again chair of pharmacology and in 1977 he was appointed Charbonnier Professor of Pharmacology, a post he held until his death.[3]

Adrenoceptor

In South Dakota, Ahlquist searched for a substitute for the Chinese plant-derived and scarce ephedrine. It has similar activity to that of adrenaline and noradrenaline - a sympathomimetic, i.e. a substance that stimulates the sympathetic nervous system. The actions of the sympathomimetics confused pharmacologists and physiologists at that time who could not explain how a single agent could have both excitatory and inhibitory effects.

In his famous work[4] Ahlquist chose six agonists, including epinephrine, norepinephrine, α-methyl noradrenaline and isoprenaline, and examined their effects on several organs, including blood vessels and the heart. He found that the six substances possessed different rank orders of potency that differed depending on the tissue. For example, the rank order of potency was "adrenaline > noradrenaline > α-methyl noradrenaline > isoprenaline" in promoting contraction of blood vessels, but the rank order was "isoprenaline > adrenaline > α-methyl noradrenaline > norepinephrine" in the heart. Ahlquist concluded that there are two different receptors for agonists. The receptors with the first rank order (that is, for example, for blood vessel contraction), he called α-adrenoceptors (alpha adrenotropic receptor) receptors while the second rank order (for instance, for the promotion of cardiac activity), he called β-adrenoceptors.

Simultaneously both cautious and forward-looking, he wrote: "Although little can be said at the present time as to the fundamental nature of the adrenotropic receptor and the difference between the alpha and beta types, this concept should be useful when studying the various actions of epinephrine, the actions and interactions of the sympathomimetic agents, and the effects of sympathetic nerve stimulation."[4]

The publication was initially dismissed, but went on to have a major impact on pharmacology.[3][5] The manuscript was first rejected by the Journal of Pharmacology and Experimental Therapeutics, but was subsequently accepted for publication by the American Journal of Physiology.[3][5] As for Ahlquist's inquiry into the nature of adrenoceptors, we now know that they are G protein-coupled receptors and humans possess a total of nine different adrenoceptors (α1A, α1B, α1D, α2A, α2B α2C, β1, β2, β3). In the field of drug therapy, his discovery laid the foundation for the development of beta blockers to treat heart disease and also reduce high blood pressure.[5][6]

Other work

Ahlquist's other scientific work also includes the pharmacology of the sympathetic nervous system. His research contribute to the discovery of tolazoline, a substance with a completely different chemical structure than the adrenaline and noradrenaline[7] and in 1958, dichloroisoprenaline the first clinically useful beta-blocker. It was discovered with his help that the peristalsis is enhanced by α-adrenoceptors and conversely inhibited by β-adrenoceptors.[8]

In his most recent essay in 1980, he looked back to the 1948 publication.[9] The impact of the 1948 publication is evident by the number of times it has been cited (2766 times as of 2011).

Awards

Ahlquist was awarded the Oscar B. Hunter Memorial Award in Therapeutics,[10] the Ciba Award for Hypertension Research and the Albert Lasker Award for Clinical Medical Research.[11]

Personal

Ahlquist met his wife Dorothy Duff Ahlquist in Seattle.

Death

Ahlquist died on April 15, 1983, in Augusta, Georgia

References

  1. ^ Sutherland JH, Carrier GO, Greenbaum LM (1983). "Dr. Raymond P. Ahlquist". The Pharmacologist. 25 (1): 73.
  2. ^ Wenger NK, Greenbaum LM (February 1984). "From adrenoceptor mechanisms to clinical therapeutics: Raymond Ahlquist, Ph.D., 1914-1983". Journal of the American College of Cardiology. 3 (2 Pt 1): 419–21. doi:10.1016/s0735-1097(84)80029-7. PMID 6141195.
  3. ^ a b c Little RC (August 1988). "Raymond P. Ahlquist (1914-1983)". Clinical Cardiology. 11 (8): 583–584. doi:10.1002/clc.4960110815. S2CID 74396544.
  4. ^ a b Ahlquist RP (June 1948). "A study of the adrenotropic receptors". The American Journal of Physiology. 153 (3): 586–600. doi:10.1152/ajplegacy.1948.153.3.586. PMID 18882199. S2CID 1518772.
  5. ^ a b c Rubin RP (December 2007). "A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics". Pharmacological Reviews. 59 (4): 289–359. doi:10.1124/pr.107.70102. PMID 18160700. S2CID 33152970.
  6. ^ Starke K (November 2011). "[The history of the α-adrenoceptor agonists]". Pharmazie in unserer Zeit (in German). 40 (6): 456–61. doi:10.1002/pauz.201100439. PMID 22028128.
  7. ^ Ahlquist RP, Huggins RA, Woodbury RA (March 1947). "The pharmacology of benzyl-imidazoline (Priscol)". The Journal of Pharmacology and Experimental Therapeutics. 89 (3): 271–88. PMID 20290430.
  8. ^ Ahlquist RP, Levy B (October 1959). "Andrenergic receptive mechanism of canine ileum". The Journal of Pharmacology and Experimental Therapeutics. 127: 146–9. PMID 13792127.
  9. ^ Ahlquist RP (November 1980). "Historical perspective. Classification of adrenoreceptors". Journal of Autonomic Pharmacology. 1 (1): 101–6. doi:10.1111/j.1474-8673.1980.tb00445.x. PMID 6122687.
  10. ^ "Oscar B. Hunter Award". American Society for Clinical Therapeutics and Pharmacology. Retrieved 2012-05-24.
  11. ^ "The Lasker Foundation - 1976 Clinical Medical Research Award". The Lasker Foundation. Retrieved 2012-05-24.

External links

Retrieved from "https://mdwiki.org/wiki/Raymond_P._Ahlquist"